Shame on you, big insurance
Comment: In response to our concern that the Axoguard HA+ Nerve Protector TM may be appropriately described by C1763 and C1765, the applicant commented that although the Axoguard HA+ Nerve Protector TM , on a superficial level, shares some attributes with products billed to those HCPCS codes, the existing codes were established for different materials and clinical uses, and thus, do not accurately describe the nominated device or its intended application
The subsequent production of inflammatory cytokines, such as IL-1, IL-6, and TNF-, by these nociceptive free endings elicit spontaneous, repetitive action potentials in sensory afferents
Tolerate both medications without severe side effects You can manage the digestive symptoms, don't experience dangerously low blood sugar, and can afford consistent access to both medications